

EXPRESS MAIL CERTIFICATE

Date 5/23/02 Label No. 2028648872-US

I hereby certify that, on the date indicated above, this paper or fee was deposited with the U.S. Postal Service & that it was addressed for delivery to the Assistant Commissioner for Patents, Washington, DC 20231 by "Express Mail Post Office to Addressee" service.

PLEASE CHARGE ANY DEFICIENCY UP TO \$300.00 OR CREDIT ANY EXCESS IN THE FEES DUE WITH THIS DOCUMENT TO OUR DEPOSIT ACCOUNT NO. 04-0100

Name (Print)

Signature

Customer No.:



07278

PATENT TRADEMARK OFFICE

Docket No.: 3368/1D888-US1

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of: Charles E. ROGLER et al.

Serial No.: 09/344,189

Group Art Unit: 1632

Filed: June 24, 1999

Examiner: P. Paras, Jr.

For: **CHRONIC HEPATITIS VIRUS INFECTION AND CLONAL  
HEPATOCELLULAR CARCINOMA IN MOUSE REPOPULATED  
LIVERS**

May 23, 2002

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Hon. Commissioner of  
Patents and Trademarks  
Washington, DC 20231

Sir:

In order to comply with 37 CFR 1.97 and 1.98, attached hereto is a copy of Form

PTO-1449<sup>1</sup> and copies of the documents listed thereon.

<sup>1</sup>To the extent that a document is listed and no copy of same is attached, then such document is not at the present time available to the undersigned or is available in the file of a parent application. If a listed document is not in the English language and an English translation is readily available, such translation is also attached; if translation is not attached it is not readily available to the undersigned. If a foreign language patent document is cited, and an English language equivalent is known to the undersigned, then such equivalent patent is also cited on the attached form along with the corresponding foreign language patent and a connecting arrow indicated therebetween; if no such English language equivalent is cited, then none is known to the undersigned.


In accordance with MPEP Sections 609 and 707.05(b), it is requested that each document cited (including any cited in applicant's specification which is not repeated on the attached Form PTO-1449) be given thorough consideration and that it be cited of record in the prosecution history of the present application by initialing Form PTO-1449 next to the document. Such initialing is requested even if the Examiner does not consider a cited document to be sufficiently pertinent to use in a rejection, or otherwise does not consider it to be prior art for any reason, or even if the Examiner does not believe that the guidelines for citation have been fully complied with. This is requested so that each document becomes listed on the face of the patent issuing on the present application.

The present Information Disclosure Statement is being submitted in compliance with 37 CFR 1.56, but the citation of such document is not to be construed as an admission that such document is necessarily relevant or prior art. No representation is intended that the cited documents represent the results of a complete search, and it is anticipated that the Examiner, in the normal course of examination, will make an independent search and will determine the best prior art consistent with 37 CFR 1.104(a) and 1.106(b) and, in the course of each search, will review for relevance every document cited on the attached form even if not initialed.

Because this Information Disclosure Statement is being filed after an Office Action has been issued but before receiving a Final Action, the statutory fee of \$180.00 under 37 C.F.R. 1.17(i)(1) is enclosed. The Commissioner is authorized to charge any additional fees required in connection with this Petition or to credit any overpayment to Deposit Account No. 04-0100.

Early and favorable consideration is earnestly solicited.

Respectfully submitted,

A handwritten signature in black ink, appearing to read "Mitchell Bernstein", written over a horizontal line.

Mitchell Bernstein, Ph.D.  
Registration No. 46,550  
Agent for Applicant(s)

DARBY & DARBY  
805 Third Avenue  
New York, NY 10022  
(212) 527-7700